The brain and the rest of the body show evident signs of aging, and degenerative illnesses have grown to be a significant global public health issue due to the rising trend of ageing. Traditional medical approaches, such as physiotherapy, medicine, and even surgery, have drawbacks like limited efficacy, protracted treatment times, and significant drug toxicity, which make it challenging to slow the progression of degenerative conditions. Although stem cells are thought to be an effective treatment for degenerative disorders, there are still some hazards and ethical concerns, such as the possibility of tumorigenicity and immunological rejection. Through proteins, RNA, and other elements of their contents, MSC-derived exosomes can behave similarly to MSCs in tissue healing, immunosuppression, and modulation of immune function.
Due to the existence of the blood-brain barrier, large molecules of drugs can not enter the brain tissue through the blood-brain barrier to exert their medicinal effects, resulting in many neurological diseases, neurodegenerative diseases can not be effectively treated.
With their small size, lipids, proteins, nucleic acids, and other signaling substances that can penetrate the blood-brain barrier to deliver drugs, cerebrovascular disease, Parkinson's, spinal cord injuries, and other diseases with the efficacy of tissue repair, mesenchymal stem cell exosomes are increasingly important therapeutic agents for the treatment of neurodegenerative diseases and other difficult neurological conditions.
ANEXT Smart Ex® for neurological illnesses, joint degenerative diseases, etc., was developed to address the limitations of current therapies and, in combination with a number of therapeutic modalities, to offer a fresh approach to the treatment of degenerative diseases.
Address: No. 1788, West Huifeng Road, Fengxian District, Shanghai, China
phone: 02160133720
